← Eichor
Study identifier: NCT07554456 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

Condition: Esophageal Squamous Cell Carcinoma  ·  Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

PhasePhase 2/Phase 3
Planned participants90
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This trial is a registrational Phase II/III, randomized, controlled, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with tislelizumab ± 5-FU in patients with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma.

This description comes directly from the study's public registry record.

Talk to the study team

Sa Xiao, PHD  ·  15013238943  ·  xiaosa@baili-pharm.com

Always discuss trial participation with your own doctor first.

Locations (1)

Beijing Cancer HospitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07554456